Leading player in the molecular diagnostics and personalized medicine space, Myriad Genetics Inc.MYGN, announced that its myChoice homologous recombination deficiencies (HRD) test will effectively ...

SALT LAKE CITY, Oct. 08, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and personalized medicine, today announced that its myChoice ® HRD test ...

Myriad myChoice CDx is the industry’s most clinically-validated genomic instability test. The test enables physicians to identify patients with tumors that have lost the ability to repair double ...

About myChoice ® HRD Myriad's myChoice HRD is the most comprehensive homologous recombination deficiency test, enabling physicians to identify tumors that have lost the ability to repair double ...

In the first clinical trial, named NOVA, Myriad showed that myChoice test can detect 100% of patients having a germline BRCA mutation, responsible for increasing the risk of breast and ovarian ...

The filing comes as recent upgrades to NCCN guidelines expand the role of testing in the treatment of ovarian cancer. Myriad Genetics this week submitted the first part of its application to the ...

Myriad Genetics, Inc. MYGN recently submitted a supplementary premarket approval (sPMA) application to the FDA for its myChoice CDx test. This will enable the identification of women suffering ...

The test that is most often used for the detection of HRD in clinical studies is the Myriad myChoice assay. However, other assays can also be used to assess biomarkers, which are indicative of HRD, ...

SALT LAKE CITY, Oct. 08, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and personalized medicine, today announced that its myChoice ® HRD test identified ...

SALT LAKE CITY, 2016-10-08 08:30 CEST (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that its myChoice® HRD test ...